Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

MSD’s Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review

Fineline Cube Dec 19, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company Deals

Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases

Fineline Cube Dec 19, 2024

US-based Photys Therapeutics, Inc. has entered into an agreement with Denmark-based Novo Nordisk A/S (NYSE:...

Company Deals

Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development

Fineline Cube Dec 19, 2024

Merck (NYSE: MRK) has announced a definitive agreement with the intention to acquire HUB Organoids...

Company Deals

BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets

Fineline Cube Dec 19, 2024

US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...

Company Medical Device

DaAn Gene Co., Ltd Receives NMPA Approval for Genetic Deafness Gene Detection Kit

Fineline Cube Dec 19, 2024

China-based DaAn Gene Co., Ltd, (SHE: 002030) affiliated with Sun Yat-sen University, has announced that...

Company Drug

MediLink Therapeutics’ YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer

Fineline Cube Dec 19, 2024

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced that the US Food and...

Company Deals

BMS Regains Exclusive Rights to ABZ-706 in Greater China

Fineline Cube Dec 19, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...

Company Drug

Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults

Fineline Cube Dec 19, 2024

China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed...

Company Drug

FDA Approves Xcovery Holdings’ Ensartinib for Untreated ALK-Positive NSCLC Patients

Fineline Cube Dec 19, 2024

On December 18, 2024, the Food and Drug Administration (FDA) granted approval for Betta Pharmaceutical...

Company Deals

INT Medical Instruments to Acquire Controlling Stake in Weiqiang Medical Technology for RMB 230 Million

Fineline Cube Dec 19, 2024

Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) has announced its intention to acquire at...

Company Drug

Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma

Fineline Cube Dec 19, 2024

Janssen-Cilag International NV has announced the submission seeking approval for an indication extension of IMBRUVICA...

Company Deals

iFlytek’s Subsidiary Xunfei Healthcare Technologies Lists on HKEX, Raises Over HKD 580 Million

Fineline Cube Dec 19, 2024

Xunfei Healthcare Technology Co., Ltd, a subsidiary of China-based information technology company iFlytek Co., Ltd...

Company Drug

Chengdu Kanghua Biological Receives NMPA Approval for Recombinant Norovirus Vaccine

Fineline Cube Dec 19, 2024

Chengdu Kanghua Biological Products Co., Ltd, (SHE: 300841), a leading biopharmaceutical company based in China,...

Company Medical Device

Sinocare Inc’s TRUE VIE CGMS Advances to 510(k) Substantive Review Stage at FDA

Fineline Cube Dec 19, 2024

Sinocare Inc (SHE: 300298), a China-based medical technology company, has announced that its continuous glucose...

Company Drug

Huadong Medicine’s HDM1005 Receives FDA Clearance for Heart Failure and Obesity Clinical Trial

Fineline Cube Dec 19, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1501 Combo in Bladder Cancer

Fineline Cube Dec 19, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Meets Primary Endpoint in Phase III NSCLC Study

Fineline Cube Dec 19, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biopharmaceutical company, has announced positive results from...

Company Deals

Hansoh Pharmaceutical Secures Global Licensing Deal with Merck for HS-10535

Fineline Cube Dec 19, 2024

China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a significant global license deal...

R&D

Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study

Fineline Cube Dec 19, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced encouraging results from a study on its...

Company Drug

UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s

Fineline Cube Dec 19, 2024

Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept...

Posts pagination

1 … 296 297 298 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.